Contributions
Abstract: PB1784
Type: Publication Only
Session title: Stem cell transplantation - Clinical
Background
It is well known that high dose chemotherapy may lead to the strengthening of oxidative stress that may be an additional factor of internal injuries and deteriorating of the patients' condition. It has been shown previously that increased oxidative stress after conditioning regimen with melphalan in patients with multiple myeloma (MM) can be considered as a reason of worthening of quality of life too.
Aims
To evaluate the influence of recombinant superoxide dismutase (Rexod®) (SOD) on some parameters of oxidative stress in MM patients during autologous stem cell transplantation (AutoSCT).
Methods
6 VV patients with median of age 50 y (39-60) were included in the trial after signing the informed consent. Levels of SOD, total SH-groups, active oxigen species, malondialdehide (MDA) were studied. 9.6 - 16x10/6/U of recombinant SOD was infused IV within 10-15 minutes at -2, +1, +7 and +14 days.
Results
Baseline level of SOD was reduced in 2 and more times compared to the norm. Futher decline of SOD was fixed on +7 day in 4 patients. Level of SOD did not change in 2 other patients. Baseline level of active oxygen species was increased (by maximum of 20 times) or decreased (by 1.3-1.8 times) in 5 patients. Levels of MDA and SH-groups did not differ from the norm. Postinduction reactions were not fixed in any case. One episode of febrile neutropenia took place in (16%) patient. Short-term elevation of transaminases of grade 1 was detected in 2 (33%) patients. Median time of neutrophils and platelets engraftment was 12 (10-15) and 14.5 (13-17) day accordingly. On day +14 restoring of SOD and active oxygen species levels to the indicators corresponding to AutoSCT were fixed. Despite the positive dynamics of significant markers of oxidative stress, they did not reach the norm in any patient.
Conclusion
The use of Rexod®, which has anti-inflamatory properties, leads to a decrease in undesirable toxic effects. It is possible that an increase in the dose and duration of Rexod® using will give a more pronounced positive effect.
Keyword(s):
Abstract: PB1784
Type: Publication Only
Session title: Stem cell transplantation - Clinical
Background
It is well known that high dose chemotherapy may lead to the strengthening of oxidative stress that may be an additional factor of internal injuries and deteriorating of the patients' condition. It has been shown previously that increased oxidative stress after conditioning regimen with melphalan in patients with multiple myeloma (MM) can be considered as a reason of worthening of quality of life too.
Aims
To evaluate the influence of recombinant superoxide dismutase (Rexod®) (SOD) on some parameters of oxidative stress in MM patients during autologous stem cell transplantation (AutoSCT).
Methods
6 VV patients with median of age 50 y (39-60) were included in the trial after signing the informed consent. Levels of SOD, total SH-groups, active oxigen species, malondialdehide (MDA) were studied. 9.6 - 16x10/6/U of recombinant SOD was infused IV within 10-15 minutes at -2, +1, +7 and +14 days.
Results
Baseline level of SOD was reduced in 2 and more times compared to the norm. Futher decline of SOD was fixed on +7 day in 4 patients. Level of SOD did not change in 2 other patients. Baseline level of active oxygen species was increased (by maximum of 20 times) or decreased (by 1.3-1.8 times) in 5 patients. Levels of MDA and SH-groups did not differ from the norm. Postinduction reactions were not fixed in any case. One episode of febrile neutropenia took place in (16%) patient. Short-term elevation of transaminases of grade 1 was detected in 2 (33%) patients. Median time of neutrophils and platelets engraftment was 12 (10-15) and 14.5 (13-17) day accordingly. On day +14 restoring of SOD and active oxygen species levels to the indicators corresponding to AutoSCT were fixed. Despite the positive dynamics of significant markers of oxidative stress, they did not reach the norm in any patient.
Conclusion
The use of Rexod®, which has anti-inflamatory properties, leads to a decrease in undesirable toxic effects. It is possible that an increase in the dose and duration of Rexod® using will give a more pronounced positive effect.
Keyword(s):